Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 12/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | ELOVL3 | Q9HB03 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847593 | 1.00 | ELOVL6 (0.45) | ELOVL6MAPK1TSHRSMN1; SMN2ENPP3 | |
| SCHEMBL2849516 | 0.88 | ABL1 (0.46) | MAPK1TSHRSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL711433 | 0.88 | ABL1 (0.46) | MAPK1TSHRSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL2847007 | 0.85 | ELOVL6 (0.49) | ELOVL6MAPK1SMN1; SMN2ENPP3ENPP1 | |
| SCHEMBL2847008 | 0.85 | ELOVL6 (0.49) | ELOVL6MAPK1SMN1; SMN2ENPP3ENPP1 | |
| SCHEMBL2847884 | 0.85 | ELOVL6 (0.45) | ELOVL6ENPP3ENPP1ENPP2STS | |
| SCHEMBL2847887 | 0.85 | ELOVL6 (0.45) | ELOVL6ENPP3ENPP1ENPP2STS | |
| SCHEMBL2852313 | 0.82 | ELOVL6 (0.56) | ELOVL6TSHRSMN1; SMN2ENPP3ENPP1 | |
| SCHEMBL2852312 | 0.82 | ELOVL6 (0.56) | ELOVL6TSHRSMN1; SMN2ENPP3ENPP1 | |
| SCHEMBL2843511 | 0.81 | ELOVL6 (0.47) | ELOVL6ENPP3ENPP1ENPP2ELOVL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2236494-B1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD KK (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-2236494-A1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | CHRM2, CHRM3, CHRM1 | ELOVL6 3399/4885MAPK1 1658/4885TSHR 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.